Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir for HIV Pre-Exposure Prophylaxis (PURPOSE 2)
NCT04925752Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Jun 2021; status: active, not recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04925752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925752.